Treatment Program for Anemia in AIDS Patients - Full Text View

Treatment Program for Anemia in AIDS Patients

This study has been completed.

Sponsored by:	R W Johnson Pharmaceutical Research Institute
Information provided by:	NIH AIDS Clinical Trials Information Service
ClinicalTrials.gov Identifier:	NCT00002022

Purpose

The objective of the Eprex (erythropoietin) Treatment Program is to provide erythropoietin for the treatment of anemia in AIDS patients.

Condition	Intervention
HIV Infections Cytopenias	Drug: Epoetin alfa

MedlinePlus related topics:

AIDS Anemia

Drug Information available for:

Zidovudine Epoetin alfa Erythropoietin

U.S. FDA Resources

Study Type:	Interventional
Study Design:	Treatment, Dose Comparison

Official Title:	Treatment Program for Anemia in AIDS Patients

Eligibility

Ages Eligible for Study:	12 Years and older
Genders Eligible for Study:	Both
Accepts Healthy Volunteers:	No

Criteria

Exclusion Criteria

Co-existing Condition:

Patients with the following are excluded:

Life expectancy < 3 months.
= or < grade 4 performance score.
AIDS-related dementia.
Uncontrolled hypertension.
Acute symptomatic opportunistic infection or other AIDS-defining illness.

Patients with the following are excluded:

Life expectancy < 3 months.
= or < grade 4 performance score.
AIDS-related dementia.
Uncontrolled hypertension.
Acute symptomatic opportunistic infection or other AIDS-defining illness.

Patients must have:

A clinical diagnosis of AIDS.
Hematocrit < 30 percent.
Endogenous serum erythropoietin level = or < 500 U/ml.
A life expectancy = or > 3 months.
> Grade 4 performance score.

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00002022

Locations


United States, New Jersey
	R W Johnson Pharmaceutical Research Institute
	Raritan, New Jersey, United States, 088690602

Sponsors and Collaborators

R W Johnson Pharmaceutical Research Institute

More Information

Study ID Numbers:	004G, I88-083
First Received:	November 2, 1999
Last Updated:	June 23, 2005
ClinicalTrials.gov Identifier:	NCT00002022
Health Authority:	United States: Food and Drug Administration

Keywords provided by NIH AIDS Clinical Trials Information Service:

Recombinant Proteins

Drugs, Investigational

Erythropoietin

Acquired Immunodeficiency Syndrome

Anemia

Zidovudine

Study placed in the following topic categories:

Epoetin Alfa

Virus Diseases

Sexually Transmitted Diseases, Viral

HIV Infections

Sexually Transmitted Diseases

Acquired Immunodeficiency Syndrome

Anemia

Zidovudine

Retroviridae Infections

Immunologic Deficiency Syndromes

Additional relevant MeSH terms:

RNA Virus Infections

Slow Virus Diseases

Immune System Diseases

Hematinics

Therapeutic Uses

Hematologic Agents

Lentivirus Infections

Infection

Pharmacologic Actions

ClinicalTrials.gov processed this record on November 30, 2008